112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG

Deutsche Bank AG bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 112,476 shares of the company's stock, valued at approximately $1,959,000. Deutsche Bank AG owned approximately 0.21% of Bicara Therapeutics at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of BCAX. DAFNA Capital Management LLC purchased a new position in shares of Bicara Therapeutics during the 4th quarter worth about $1,838,000. Deep Track Capital LP increased its position in Bicara Therapeutics by 151.0% during the fourth quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock worth $34,840,000 after purchasing an additional 1,203,148 shares during the last quarter. Braidwell LP increased its position in Bicara Therapeutics by 20.7% during the fourth quarter. Braidwell LP now owns 2,000,659 shares of the company's stock worth $34,851,000 after purchasing an additional 343,059 shares during the last quarter. Blackstone Inc. grew its stake in shares of Bicara Therapeutics by 40.5% during the 4th quarter. Blackstone Inc. now owns 913,060 shares of the company's stock valued at $15,906,000 after buying an additional 263,060 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Bicara Therapeutics by 278.4% during the 4th quarter. Bank of America Corp DE now owns 33,677 shares of the company's stock worth $587,000 after buying an additional 24,777 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BCAX. Wall Street Zen cut shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Wedbush restated an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a report on Friday, May 23rd. Stifel Nicolaus set a $48.00 price target on Bicara Therapeutics in a report on Thursday, March 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, HC Wainwright dropped their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $31.86.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock traded down $0.02 on Thursday, hitting $9.44. 1,042,158 shares of the company's stock traded hands, compared to its average volume of 545,425. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $28.09. The firm's 50-day moving average is $12.62 and its 200 day moving average is $14.56.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). On average, analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.